Status:
COMPLETED
Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome
Lead Sponsor:
I.M. Sechenov First Moscow State Medical University
Conditions:
Covid19
ARDS
Eligibility:
All Genders
18-80 years
Brief Summary
Non-invasive ventilation can allow to avoid intubation and improve outcomes in moderate-to-severe COVID-19-associated acute respiratory distress-syndrome (ARDS). Data on NIV parameters adjustment base...
Detailed Description
In December 2019, an outbreak of a novel coronavirus emerged in Wuhan, China and rapidly spread worldwide. The World Health Organization (WHO) declared the outbreak a pandemic on March 11th, 2020. The...
Eligibility Criteria
Inclusion
- at least one of the following criteria: fatigue, Patrick scale 5 points, SpO2\<92% on standard oxygen therapy (\<15 l/min) or continuous positive airway pressure (CPAP)-therapy with oxygen flow\<15 l/min
Exclusion
- pregnancy
- age less than 18 or more than 80 years
- life-threatening heart rhythm abnormalities and/or systolic blood pressure \< 80 mmHg despite norepinephrine at a dose \> 2 µg/kg/min
- primary lung diseases (e.g. interstitial lung diseases, lung emphysema) or tumour metastases in lungs
- chronic decompensated diseases with extrapulmonary organ dysfunction (tumour progression, liver cirrhosis, congestive heart failure)
- Glasgow cona score \< 14
- inability to swallow
- upper airways obstruction
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04667923
Start Date
October 1 2020
End Date
August 31 2021
Last Update
November 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sechenov University clinic #4
Moscow, Russia